Value added medicines: what value repurposed medicines might bring to society?

par Toumi, Mondher, Rémuzat, Cécile
Publié dans J Mark Access Health Policy (2016)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France

par Rémuzat, Cécile, Toumi, Mondher, Falissard, Bruno
Publié dans J Mark Access Health Policy (2013)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry

par Rémuzat, Cécile, Toumi, Mondher, Falissard, Bruno
Publié dans J Mark Access Health Policy (2013)

Market access pathways for cell therapies in France

par Rémuzat, Cécile, Toumi, Mondher, Jørgensen, Jesper, Kefalas, Panos
Publié dans J Mark Access Health Policy (2015)

Advanced therapy medicinal products: current and future perspectives

par Hanna, Eve, Rémuzat, Cécile, Auquier, Pascal, Toumi, Mondher
Publié dans J Mark Access Health Policy (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials

par Hanna, Eve, Rémuzat, Cecile, Auquier, Pascal, Toumi, Mondher
Publié dans J Mark Access Health Policy (2016)

Gene therapies development: slow progress and promising prospect

par Hanna, Eve, Rémuzat, Cécile, Auquier, Pascal, Toumi, Mondher
Publié dans J Mark Access Health Policy (2017)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines

par Lach, Krzysztof, Dziwisz, Michal, Rémuzat, Cécile, Toumi, Mondher
Publié dans J Mark Access Health Policy (2017)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions

par Frybourg, Sandrine, Remuzat, Cécile, Kornfeld, Åsa, Toumi, Mondher
Publié dans J Mark Access Health Policy (2015)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry

par Badora, Karolina, Caban, Aleksandra, Rémuzat, Cécile, Dussart, Claude, Toumi, Mondher
Publié dans J Mark Access Health Policy (2017)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey

par Angermeyer, Matthias C, Millier, Aurélie, Rémuzat, Cécile, Refaï, Tarek, Toumi, Mondher
Publié 2013

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments

par Massetti, Marc, Aballéa, Samuel, Videau, Yann, Rémuzat, Cécile, Roïz, Julie, Toumi, Mondher
Publié dans J Mark Access Health Policy (2015)

Key drivers for market penetration of biosimilars in Europe

par Rémuzat, Cécile, Dorey, Julie, Cristeau, Olivier, Ionescu, Dan, Radière, Guerric, Toumi, Mondher
Publié dans J Mark Access Health Policy (2017)

Overview of external reference pricing systems in Europe

par Rémuzat, Cécile, Urbinati, Duccio, Mzoughi, Olfa, El Hammi, Emna, Belgaied, Wael, Toumi, Mondher
Publié dans J Mark Access Health Policy (2015)

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states

par Rémuzat, Cécile, Kapuśniak, Anna, Caban, Aleksandra, Ionescu, Dan, Radière, Guerric, Mendoza, Cyril, Toumi, Mondher
Publié dans J Mark Access Health Policy (2017)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

par Toumi, Mondher, Motrunich, Anastasiia, Millier, Aurélie, Rémuzat, Cécile, Chouaid, Christos, Falissard, Bruno, Aballéa, Samuel
Publié dans J Mark Access Health Policy (2017)

Current process and future path for health economic assessment of pharmaceuticals in France

par Toumi, Mondher, Rémuzat, Cécile, El Hammi, Emna, Millier, Aurélie, Aballéa, Samuel, Chouaid, Christos, Falissard, Bruno
Publié dans J Mark Access Health Policy (2015)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

par Chouaid, Christos, Borget, Isabelle, Braun, Eric, Bazil, Marie-Laure, Schaetz, Dominique, Rémuzat, Cécile, Toumi, Mondher
Publié dans Target Oncol (2016)

Pharmaceutical expenditure forecast model to support health policy decision making

par Rémuzat, Cécile, Urbinati, Duccio, Kornfeld, Åsa, Vataire, Anne-Lise, Cetinsoy, Laurent, Aballéa, Samuel, Mzoughi, Olfa, Toumi, Mondher
Publié dans J Mark Access Health Policy (2014)

Novel methodology for pharmaceutical expenditure forecast

par Vataire, Anne-Lise, Cetinsoy, Laurent, Aballéa, Samuel, Rémuzat, Cécile, Urbinati, Duccio, Kornfeld, Åsa, Mzoughi, Olfa, Toumi, Mondher
Publié dans J Mark Access Health Policy (2014)